ReviewCurrent rheumatology reports2015
The ASAS Criteria for Axial Spondyloarthritis: Strengths, Weaknesses, and Proposals for a Way Forward.
Review in Current rheumatology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- An Overview of Adalimumab Therapy for Ankylosing Spondylitis.Current rheumatology reviews · 2024Pooled it
- A Comprehensive Clinical Decision Support System for the Early Diagnosis of Axial Spondyloarthritis: Multi-Sequence MRI, Clinical Risk Integration, and Explainable Segmentation.Diagnostics (Basel, Switzerland) · 2026Article
- Biomarkers in axial spondyloarthritis diagnosis: from clinical signs to multi-omics integration.Frontiers in immunology · 2026Review
- Imaging pathways in spondyloarthritis: integrating radiography, ultrasonography, magnetic resonance imaging, low-dose computed tomography, and artificial intelligence methods : Radiology and AI in SpA.Rheumatology international · 2025Review
- Antigen-driven T cell responses in rheumatic diseases: insights from T cell receptor repertoire studies.Nature reviews. Rheumatology · 2025Review
- Long-Term Follow-Up of Patients with Axial Spondyloarthritis in Real-Life Setting: Results from Greece of the Multi-Country Registry Proof Study.Mediterranean journal of rheumatology · 2024Article
- Characteristics and burden of disease in patients with radiographic versus non-radiographic axial spondyloarthritis in the ASRI cohort.Irish journal of medical science · 2024Article
- An Assessment of Thyroid Dysfunction and Related Parameters in Patients With Systemic Autoimmune Disorders.Cureus · 2023Article
- The serum uric acid is longitudinally related to patients global assessment of disease activity in male patients with axial spondyloarthritis.BMC musculoskeletal disorders · 2022Article
- Heterogeneity of axial spondyloarthritis: genetics, sex and structural damage matter.RMD open · 2022Article
- Australian Consensus Statements for the Assessment and Management of Non-radiographic Axial Spondyloarthritis.Rheumatology and therapy · 2022Article
- Therapeutic Potential of Triptolide in Treating Bone-Related Disorders.Frontiers in pharmacology · 2022Review
- The Annual Diagnostic Prevalence of Ankylosing Spondylitis and Axial Spondyloarthritis in the United States Using Medicare and MarketScan Databases.ACR open rheumatology · 2021Article
- The Effect of Etanercept in Nonradiographic Axial Spondyloarthritis by Stratified C-Reactive Protein Levels.ACR open rheumatology · 2021Article
- Prevalence of pistol-grip deformity in patients with axial spondyloarthritis.European journal of rheumatology · 2021Article
- Value-Based Healthcare in Rheumatology: Axial Spondyloarthritis and Beyond.Current rheumatology reports · 2021Review
- Axial spondyloarthritis: concept, construct, classification and implications for therapy.Nature reviews. Rheumatology · 2021Review
- Genetics and the axial spondyloarthritis spectrum.Rheumatology (Oxford, England) · 2020Review
- Validity and reliability of EQ-5D-5L among patients with axial spondyloarthritis in Singapore.European journal of rheumatology · 2020Article
- The incidence of bone marrow oedema at the sacroiliac joints in a non-rheumatological population - a retrospective cohort study.BMC musculoskeletal disorders · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Classification criteria should facilitate selection of similar patients for clinical and epidemiologic studies, therapeutic trials, and research on etiopathogenesis to enable comparison of results across studies from different centers. We critically appraise the validity and performance of the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axial spondyloarthritis (axSpA). It is still debatable whether all patients fulfilling these criteria should be considered as having true axSpA. Patients with radiographically evident disease by the ASAS criteria are not necessarily identical with ankylosing spondylitis (AS) as classified by the modified New York criteria. The complex multi-arm selection design of the ASAS criteria induces considerable heterogeneity among patients so classified, and applying them in settings with a low prevalence of axial spondyloarthritis (SpA) greatly increases the proportion of subjects falsely classified as suffering from axial SpA. One of the unmet needs in non-radiographic form of axial SpA is to have reliable markers that can identify individuals at risk for progression to AS and thereby facilitate early intervention trials designed to prevent such progression. We suggest needed improvements of the ASAS criteria for axSpA, as all criteria sets should be regarded as dynamic concepts open to modifications or updates as our knowledge advances.
Indexed as
Identifiers
26286179What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.